论文部分内容阅读
嵌合抗原受体修饰T细胞在治疗血液系统恶性肿瘤中取得了良好治疗效果。嵌合抗原受体修饰T细胞是通过基因修饰方法获得针对肿瘤细胞表面特定抗原的特异性T细胞。嵌合抗原受体具有赋予T细胞更强的靶向性并能打破宿主免疫耐受状态等理论优势,但由于乳腺癌等实体肿瘤的脱靶效应、免疫细胞不易进入瘤体内部等因素,该应用尚处于临床前实验阶段。本文就嵌合抗原受体修饰T细胞在乳腺癌治疗中应用的研究进展作一综述。
Chimeric antigen receptor modified T cells in the treatment of hematological malignancies have achieved good therapeutic effect. Chimeric antigen receptor-modified T cells are specific T cells obtained by genetic modification to specific antigens on tumor cell surface. Chimeric antigen receptors have the advantages of conferring stronger T cell targeting and breaking host immune tolerance status. However, due to the off-target effect of solid tumors such as breast cancer and the inaccessibility of immune cells into the tumor, Still in the preclinical experimental stage. This review summarizes the progress in the application of chimeric antigen receptor modified T cells in the treatment of breast cancer.